Table of contents

• Overview of the trial program
• Who is being studied
• Trial phases and study design
• Main endpoints being measured
• Trials by condition
• What these studies may mean for patients

Overview of the trial program

The trial data show a broad research program for Lutetium (177Lu) Oxodotreotide, with studies in neuroendocrine tumors, meningioma, neuroblastoma, and extensive-stage small cell lung cancer.^[1] Most studies are interventional, which means the researchers give a treatment and then measure what happens.^[1]

Across the trials, the main goals are to study efficacy, safety, tolerability, and radiation dose to organs and tumors.^[1] Several studies compare Lutetium (177Lu) Oxodotreotide with standard care, active surveillance, or other treatment strategies.^[1]

Who is being studied

The largest group of trials includes patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including advanced disease, well-differentiated tumors, and tumors with somatostatin receptor positivity.^[1] Some studies focus on midgut neuroendocrine tumors, small intestinal neuroendocrine neoplasms, or patients with liver metastases.^[1]

Other studies include people with recurrent or refractory meningioma, children with recurrent or refractory neuroblastoma, adolescents with GEP-NETs or pheochromocytoma/paraganglioma, and patients with extensive-stage small cell lung cancer.^[1] One study also includes children and adolescents with recurrent or relapsed solid tumors that express somatostatin receptors.^[1]

Trial phases and study design

The studies span Phase 1, Phase 2, and Phase 3 research.^[1] Phase 1 trials are used mainly to define dose, safety, or tolerability, while Phase 2 and Phase 3 trials look more closely at how well the treatment works in larger groups.^[1]

Some studies are randomized, meaning patients are assigned by chance to different treatment groups.^[1] Others compare Lutetium (177Lu) Oxodotreotide with active surveillance, best supportive care, or standard treatment choices.^[1]

Main endpoints being measured

The most common endpoint is progression-free survival (PFS), which is the time before the cancer gets worse or the patient dies from any cause.^[1] One adjuvant study uses relapse-free survival (RFS), which measures time from randomization to relapse or death.^[1]

Other studies measure disease control rate, overall survival, response rate, and time to deterioration in health-related quality of life.^[1] Safety endpoints include adverse events, serious adverse events, dose-limiting toxicities, laboratory toxicities, and hematologic toxicity.^[1]

Some trials also measure absorbed radiation dose in organs such as the kidney and bone marrow, or tumor uptake on imaging tests like PET-CT or SPECT/CT.^[1]

Trials by condition

Neuroendocrine tumors are the main focus of the trial program.^[1] Several Phase 3 studies test Lutetium (177Lu) Oxodotreotide as first-line treatment in advanced GEP-NETs or as part of treatment strategies after progression.^[1] Other studies look at retreatment, adjuvant use after surgery for stage III small intestinal disease, or less intensive schedules for slowly progressive midgut tumors.^[1]

For meningioma, the trials ask whether Lutetium (177Lu) Oxodotreotide can help control recurrent or refractory disease, including grades 2 and 3.^[1] The main outcomes here are progression-free survival, often assessed by MRI-based criteria.^[1]

In children and adolescents, the studies include recurrent or refractory neuroblastoma and other relapsed solid tumors with somatostatin receptor expression.^[1] These trials focus on finding the maximum tolerated dose, early response, safety, and quality of life.^[1]

One study in extensive-stage small cell lung cancer examines Lutetium (177Lu) Oxodotreotide with carboplatin, etoposide, and atezolizumab, first to define the dose and then to test overall survival.^[1]

What these studies may mean for patients

These trials show that Lutetium (177Lu) Oxodotreotide is being tested in both earlier and more advanced research settings.^[1] Some studies ask whether it should be used earlier in treatment, while others test whether it can help after disease progression or in special groups such as children and adolescents.^[1]

For patients, the key point is that trial participation depends on the cancer type, tumor features such as somatostatin receptor positivity, age group, and previous treatment history.^[1] The studies are designed to answer practical questions about benefit, safety, and how to measure response in different diseases.^[1]